Altered Prostanoid Signaling Contributes to Increased Skin Tumorigenesis in Tpl2 Knockout Mice

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  DeCicco Skinner, Kathleen L ^a   Nolan, Sabrina J ^a   Deshpande, Monika M ^b   Trovato, Erika L ^a,b   Dempsey, Taylor A ^a   Wiest, Jonathan S ^b  

^a AMERICAN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE LOCATION; IN VIVO STUDY; INFLAMMATION; KERATINOCYTE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; SKIN PAPILLOMA; TPL2 GENE; WESTERN BLOTTING; WILD TYPE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; KERATINOCYTES; MALE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; PROSTAGLANDINS; PROTO-ONCOGENE PROTEINS; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION; SKIN; TETRADECANOYLPHORBOL ACETATE;

EID: 84874094810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056212     Document Type: Article

References (53)

1. Khavari TA, Rinn J, (2007) Ras/Erk MAPK signaling in epidermal homeostasis and neoplasia. Cell Cycle 6: 2928-2931.
2. Aoki M, Akiyama T, Miyoshi J, Toyoshima K, (1991) Identification and characterization of protein products of the cot oncogene with serine kinase activity. Oncogene 6: 1515-1519.
3. Patriotis C, Makris A, Chernoff J, Tsichlis PN, (1994) Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase. Proc Natl Acad Sci U S A 91: 9755-9759.
4. Salmeron A, Ahmad TB, Carlile GW, Pappin D, Narsimhan RP, et al. (1996) Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J 15: 817-826.
5. Patriotis C, Makris A, Bear SE, Tsichlis PN, (1993) Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci U S A 90: 2251-2255.
6. Chiariello M, Marinissen MJ, Gutkind JS, (2000) Multiple mitogen-activated protein kinase signaling pathways connect the Cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol 20: 1747-1758.
7. Tsatsanis C, Patriotis C, Tsichlis PN, (1998) Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kappa B. Oncogene. 17: 2609-2618.
8. Belich MP, Salmerón A, Johnston LH, Ley SC, (1999) TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein NF-kappaB1 p105. Nature 397: 363-368.
9. Lang V, Symons A, Watton S J, Janzen J, Soneji Y, et al. (2004) ABIN-2 forms a ternary complex with TPL-2 and NF-κB1 p105 and is essential for TPL-2 protein stability. Mol Cell Biol 24: 5235-5248.
10. Beinke S, Deka J, Lang V, Belich MP, Walker PA, et al. (2003) NF-kappaB1 p105 negatively regulates TPL-2 MEK kinase activity. Mol Cell Biol 23: 4739-4752.
11. Miyoshi J, Higashi T, Mukai H, Ohuchi T, Kakunaga T, (1991) Structure and transforming potential of the human cot oncogene encoding a putative protein kinase. Mol Cell Biol 11: 4088-4096.
12. Ceci JD, Patriotis CP, Tsatsanis C, Makris AM, Kovatch R, et al. (1997) Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev 11: 688-700.
13. Tsatsanis C, Spandidos DA, (2000) The role of oncogenic kinases in human cancer. Int J Mol Med 5: 583-590.
14. Sourvinos G, Tsatsanis C, Spandidos DA, (1999) Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 18: 4968-4973.
15. Clark AM, Reynolds SH, Anderson M, Wiest JS, (2004) Mutational activation of the MAP3K8 protooncogene in lung cancer. Genes Chromosomes Cancer 41: 99-108.
16. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972.
17. Vougioukalaki M, Kanellis DC, Gkouskou K, Eliopoulos AG, (2011) Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett 304: 80-89.
18. Tsatsanis C, Vaporidi K, Zacharioudaki V, Androulidaki A, Sykulev Y, et al. (2008) Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells. Proc Natl Acad Sci U S A 105: 2987-2992.
19. DeCicco-Skinner KL, Trovato EL, Simmons JK, Lepage PK, Wiest JS, (2011) Loss of tumor progression locus 2 (Tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis. Oncogene 30: 389-397.
20. de Visser KE, Eichten A, Coussens LM, (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1): 24-37.
21. Funk CD, (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875.
22. Dempke W, Rie C, Grothey A, Schmoll HJ, (2001) Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127: 411-417.
23. Cao Y, Prescott SM, (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286.
24. Trifan OC, Hla T, (2003) Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 7: 207-222.
25. An KP, Athar M, Tang X, Katiyar SK, Russo J, et al. (2002) Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 76: 73-80.
26. Chun KS, Surh YJ, (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 68: 1089-1100.
27. Müller-Decker K, Kopp-Schneider A, Marks F, Seibert K, Furstenberger G, (1998) Localization of prostaglandin H synthase isozymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. Mol Carcinogenesis 23: 36-44.
28. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis. 30: 377-386.
29. Sung YM, He G, Fischer SM, (2005) Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 65: 9304-9311.
30. Maldve RE, Kim Y, Muga SJ, Fischer SM, (2000) Prostaglandin E(2) regulation of cyclooxygenase expression in keratinocytes is mediated via cyclic nucleotide-linked prostaglandin receptors. J Lipid Res 41: 873-881.
31. Ansari KM, Rundhaug JE, Fischer SM, (2008) Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation. Mol Cancer Res. 6: 1003-1016.
32. Klein T, Shephard P, Kleinert H, Kömhoff M, (2007) Regulation of cyclooxygenase-2 expression by cyclic AMP. Biochimica et Biophysica Acta 1773: 1605-1618.
33. Abramovitch R, Tavor E, Jacob-Hirsch J, Zeira E, Amariglio N, et al. (2004) A Pivotal Role of Cyclic AMP-Responsive Element Binding Protein in Tumor Progression. Cancer Res 64: 1338-1346.
34. Lichti U, Anders J, Yuspa SH, (2008) Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient mice. Nat Protoc 3: 799-810.
35. Sung YM, He G, Hwang DH, Fischer SM, (2006) Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development. Oncogene 25: 5507-5516.
36. Xie J, (2008) Molecular biology of basal and squamous cell carcinomas. Adv Exp Med Biol 624: 241-251.
37. Mueller MM, (2006) Inflammation in epithelial skin tumours: old stories and new ideas. Eur J Cancer 42: 735-744.
38. Coussens LM, Werb Z, (2002) Inflammation and cancer. Nature 420: 860-867.
39. Müller-Decker K, Fürstenberger G, (2007) The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog 46: 705-710.
40. Ghosh N, Chaki R, Mandal V, Mandal SC, (2010) COX-2 as a target for cancer chemotherapy. Pharmacol Rep 62: 233-244.
41. Müller-Decker K, Neufang G, Berger I, Neumann M, Marks F, et al. (2002) Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 99: 12483-12488.
42. Fischer SM, (2002) Is cyclooxygenase-2 important in skin carcinogenesis? J Environ Pathol Toxicol Oncol 21: 183-191.
43. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, et al. (2002) Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 62: 3395-3401.
44. Hussain M, Javeed A, Ashraf M, Al-Zaubai N, Stewart A, et al. (2012) Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. Pharmacol Res 66: 7-18.
45. Furstenberger G, Marks F, (1978) Indomethacin inhibition of cell proliferation induced by the phorbol ester TPA is reversed by prostaglandin E2 in mouse epidermis in vivo. Biochem Biophys Res Commun 84: 1103-1111.
46. Pentland AP, Needleman P, (1986) Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis. J Clin Invest 77: 246-251.
47. Aizu E, Yamamoto S, Nakadate T, Kato R, (1990) Differential effects of various skin tumor-promoting agents on prostaglandin E2 release from primary cultures of mouse epidermal cells. Eur J Pharmacol 182: 19-28.
48. Rundhaug JE, Fischer SM, (2010) Molecular Mechanisms of Mouse Skin Tumor Promotion. Cancers (Basel) 2: 436-482.
49. Lee JL, Kim A, Kopelovich L, Bickers DR, Athar M, (2005) Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer. J Invest Dermatol 125: 818-825.
50. Brouxhon S, Konger RL, VanBuskirk J, Sheu T-j, Ryan J, et al. (2007) Deletion of prostagandin E2 EP2 receptor protects against ultraviolet-induced carcinogenesis, but increases tumor aggressiveness. J Invest Dermatol 127: 439-446.
51. Ansari KM, Sung YM, He G, Fischer SM, (2007) Prostaglandin receptor EP2 is responsible for cyclooxygenase-2 induction by prostaglandin E2 in mouse skin. Carcinogenesis 28: 2063-2068.
52. Chun KS, Lao HC, Trempus CS, Okada M, Langenbach R, (2009) The prostaglandin receptor EP2 activates multiple signaling pathways and β- arrestin 1 complex formation during mouse skin papilloma development. Carcinogenesis 30: 1620-1627.
53. Dajani EZ, Islam K, (2008) Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol 59: 117-133.